Accession Number:

ADA619622

Title:

Innovative T Cell-Targeted Therapy for Ovarian Cancer

Descriptive Note:

Final rept. 30 Sep 2011-29 Jul 2014

Corporate Author:

M D ANDERSON CANCER CENTER HOUSTON TX

Personal Author(s):

Report Date:

2014-10-01

Pagination or Media Count:

405.0

Abstract:

Major advances have been made in two main areas. Firstly, Receptor tyrosine kinase-like orphan receptor-1 ROR1 was identified as a tumor antigen expressed on ovarian cancer OvCa, but not expressed on normal tissues. Second generation chimeric antigen receptors CARs were designed with CD3z and either CD28 or CD137 endodomains fused to the antigen-binding region of a ROR1-specific monoclonal antibody clone 4A5. CARs were stably expressed in T cells following Sleeping Beauty SB11 transposition and propagation on ROR1 artificial antigen presenting cells aAPC. Re-directed cytolysis of ROR1 OvCa cell lines by CAR T cells was demonstrated. Secondly, the anti-tumor activity of gd T cells was harnessed to kill OvCa. Our aAPC were used to massively expand for the first time a polyclonal population of gd T cells for immunotherapy. OvCa cell lines and xenografts were eliminated by these massively expanded polyclonal gd T cells. gd T cells are HLA-unrestricted and rapid expansion with our novel aAPCs may also have utility as off the shelf therapy for Ebola virus and other virus and bacteria mediated outbreaks. Based on this work, a ROR1 CAR clinical trial has been registered at ClinicalTrials.gov and opened in January 2015 NCT02194374.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE